PlatformFebruary 24, 2026

AI-MSC Platform Update Highlights Translational Progress

The company has expanded platform validation work linking stem-cell differentiation control with disease-focused development.

Qgenetics has continued to extend the translational scope of its AI-MSC platform through disease-focused validation work. The latest update emphasizes tighter integration between target selection, medicinal chemistry, and differentiation control.

This work is intended to strengthen downstream development efficiency across osteoporosis, osteoarthritis, and metabolic indications connected to the Soft Aging strategy.

The company expects these platform improvements to support both internal pipeline expansion and future partnering discussions.